Gas Stations Quietly Charging Drivers $1 More per Gallon for This 1 Reason
Across several states, including Florida, gas stations are increasingly charging higher prices per gallon for credit card users. The difference is often as much as $1 more per gallon compared to the cash price, a markup that can quietly add up on a full tank.
While it's legal for businesses to charge extra for credit card transactions, most states require that these fees be clearly disclosed to customers. Some gas stations are skirting that line by posting notices in fine print on the pump or signage that drivers may not easily notice.
The result? Many drivers swipe their cards expecting the advertised street price, only to find out after the fact that they've been charged significantly more. With gas prices already pushing budgets, an extra $10 or $20 per fill-up can make a real impact.
Consumer watchdogs point out that while the surcharge itself may be legal, the lack of upfront transparency could border on deceptive business practices. And as long as stations get away with it, the hidden fee trend may continue to grow.
The best way to avoid surprise charges is to pay close attention to posted pricing at the pump and read the fine print before fueling. Some stations make their cash-versus-credit prices obvious, while others bury the details in pump stickers or small signs.
Apps and rewards programs can also help soften the blow.
Ultimately, small habits—like checking for price differences or choosing stations that don't penalize credit card users—can save hundreds over the course of a year. With gas expenses averaging over $2,400 per driver annually, every dollar counts.Gas Stations Quietly Charging Drivers $1 More per Gallon for This 1 Reason first appeared on Men's Journal on Jul 13, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Why Google should 'walk away' from Waymo
Needham & Company senior media and internet analyst Laura Martin joins Market Domination with Josh Lipton to explain why Alphabet (GOOG, GOOGL) should ditch Waymo and focus on generative artificial intelligence (AI) instead. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Related videos The £70bn pension tax raid Reeves may not be able to resist 10 shares I wouldn't want to hold in a stock market crash After falling 16% in a day, this stock's on my list of shares to buy in August This FTSE 250 trust is easily beating the global index in 2025. Time to buy? Sign in to access your portfolio
Yahoo
11 minutes ago
- Yahoo
EMCOR Group (EME) Sees EPS Surge as Net Income Climbs to US$241 Million
EMCOR Group recently announced a regular quarterly cash dividend of $0.25 per common share, to be paid on July 31, 2025. This steady dividend approach aligns with the company's robust quarterly performance, which saw net income rise to $241 million and EPS increase substantially year-over-year. Additionally, the ongoing share buyback program has strengthened shareholder returns. Despite the broader market's moderate growth of 1.4% over the past week and 17% over the past year, EMCOR's notable share repurchases and solid financial outcomes appear to have amplified investor confidence, contributing to the company's impressive 55% stock price surge last quarter. We've spotted 1 risk for EMCOR Group you should be aware of. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. EMCOR Group's recent announcement of a quarterly dividend and the implementation of its share buyback program underline its commitment to enhancing shareholder returns. Despite a potential downside to the current share price of US$635.06, which exceeds the consensus analyst price target of US$549.57 by 13.46%, these actions could continue to buoy investor confidence. The company's performance over the past five years, with a total return exceeding 844.60%, showcases its robust long-term trajectory. In the last year, EMCOR's share performance exceeded both the broader market's 17.2% and the US Construction industry's 54.2% return, highlighting its strong standing relative to peers. The successful integration of acquisitions and strategic diversification into sectors like data centers and healthcare is anticipated to impact future revenue positively. This, coupled with operational efficiencies and strong revenue collaboration, may reinforce earnings projections. However, EMCOR's earnings forecasts of a 6.2% annual growth rate lag behind the broader market's 14.9% forecast, which could present challenges in meeting broader industry expectations. The company's impressive share price rise of 55% last quarter signals optimism, though its current value being above the target may indicate overvaluation concerns. Nevertheless, the consistent cash flow and healthy margins underscore its potential resilience against margin pressures, supply chain challenges, and other economic uncertainties. As analysts estimate revenue growth to 7.9% annually over the next three years, any tangible improvement in operational metrics could shift the valuation outlook positively. Unlock comprehensive insights into our analysis of EMCOR Group stock in this financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include EME. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
